Development of novel recombinant adenoviruses

2023 Fiscal Year Final Research Report

• Project/Area Number: 20H00664
• Research Category: Grant-in-Aid for Scientific Research (A)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Medium-sized Section 90:Biomedical engineering and related fields
• Research Institution: Osaka University
• Principal Investigator: Mizuguchi Hiroyuki 大阪大学, 大学院薬学研究科, 教授 (50311387)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: ウイルス / 遺伝子 / 癌 / 免疫学 / バイオテクノロジー

Outline of Final Research Achievements

Replication-incompetent adenovirus (Ad) vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. In addition, oncolytic Ad are among the most promising oncolytic viruses. In this study, we have done several basic studies about the improvement of recombinant Ad. Following recombinant Ad were developed and evaluated. Oncolytic Ad fully composed of human Ad serotype 35, hexon/fiber-modified Ad vectors for circumventing neutralizing anti-Ad antibodies, and Ad vectors having gene editing functions.

Free Research Field

分子生物学

Academic Significance and Societal Importance of the Research Achievements

本研究は、腫瘍溶解性AdやAdベクターワクチン、さらにはゲノム編集と組み合わせた遺伝子治療への応用に向けて、研究代表者が有する世界で最先端のAd改変技術を駆使することで、新しい視点からベクター開発（改良）と関連する応用研究を進めるものであり、独創性が高く、学術的意義が大きい。また、日本独自の高性能ベクター開発は、その汎用性の観点から国益を考えたうえでも最重要研究課題の一つであり、その社会的意義は極めて大きい。